Sigdel Tara, Nguyen Mark, Liberto Juliane, Dobi Dejan, Junger Henrik, Vincenti Flavio, Laszik Zoltan, Sarwal Minnie M
Department of Surgery, University of California, San Francisco, San Francisco, CA, United States.
Department of Nephrology, University of California, San Francisco, San Francisco, CA, United States.
Front Med (Lausanne). 2019 Oct 1;6:213. doi: 10.3389/fmed.2019.00213. eCollection 2019.
There is an urgent need to develop and implement low cost, high-throughput standardized methods for routine molecular assessment of transplant biopsies. Given the vast archive of formalin-fixed and paraffin-embedded (FFPE) tissue blocks in transplant centers, a reliable protocol for utilizing this tissue bank for clinical validation of target molecules as predictors of graft outcome over time, would be of great value. We designed and optimized assays to quantify 19 target genes, including previously reported set of tissue common rejection module (tCRM) genes. We interrogated their performance for their clinical utility for detection of graft rejection and inflammation by analyzing gene expression microarrays analysis of 163 renal allograft biopsies, and subsequently validated in 40 independent FFPE archived kidney transplant biopsies at a single center. A QPCR (Fluidigm) and a barcoded oligo-based (NanoString) gene expression platform were compared for evaluation of amplification of gene expression signal for 19 genes from degraded RNA extracted from FFPE biopsy sections by a set protocol. Increased expression of the selected 19 genes, that reflect a combination of specific cellular infiltrates (8/19 genes) and a graft inflammation score (11/19 genes which computes the tCRM score allowed for segregation of kidney transplant biopsies with stable allograft function and normal histology from those with histologically confirmed acute rejection (AR; = 0.0022, QPCR; = 0.0036, barcoded assay) and many cases of histological borderline inflammation (BL). Serial biopsy shaves used for gene expression were also processed for hybridization (ISH) for a subset of genes. ISH confirmed a high degree of correlation of signal amplification and tissue localization. Target gene expression amplification across a custom set of genes can identify AR independent of histology, and quantify inflammation from archival kidney transplant biopsy tissue, providing a new tool for clinical correlation and outcome analysis of kidney allografts, without the need for prospective kidney biopsy biobanking efforts.
迫切需要开发并实施低成本、高通量的标准化方法,用于移植活检的常规分子评估。鉴于移植中心有大量福尔马林固定石蜡包埋(FFPE)组织块存档,若能有一个可靠方案利用该组织库对靶分子进行临床验证,以预测移植结果随时间的变化,将具有重要价值。我们设计并优化了检测方法,以定量19个靶基因,包括先前报道的一组组织共同排斥模块(tCRM)基因。我们通过分析163例肾移植活检组织的基因表达微阵列,研究了它们在检测移植排斥和炎症方面的临床效用,随后在单一中心的40例独立FFPE存档肾移植活检组织中进行了验证。比较了一种定量聚合酶链反应(QPCR,Fluidigm)和一种基于条形码寡核苷酸的(NanoString)基因表达平台,以评估按照既定方案从FFPE活检切片提取的降解RNA中19个基因的基因表达信号扩增情况。所选19个基因表达增加,这些基因反映了特定细胞浸润(8/19个基因)和移植炎症评分(11/19个基因,计算tCRM评分)的组合,可将具有稳定移植功能和正常组织学的肾移植活检与组织学确诊的急性排斥(AR;QPCR,P = 0.0022;条形码检测,P = 0.0036)及许多组织学临界炎症(BL)病例区分开来。用于基因表达的系列活检切片也针对一部分基因进行了原位杂交(ISH)处理。ISH证实了信号扩增与组织定位的高度相关性。跨一组定制基因的靶基因表达扩增可独立于组织学识别AR,并定量存档肾移植活检组织中的炎症,为肾移植的临床相关性和结果分析提供了一种新工具,而无需进行前瞻性肾活检生物样本库工作。